In-vitro diagnostics (IVD) are used to detect diseases, infections, and conditions and also monitor a person’s state of health and therapeutic procedures by examining specimens derived from the human body such as tissue, blood, stools, urine and the other body fluids. Significant technologies incorporated in in-vitro diagnostics are polymerase chain reaction, microarray techniques, sequencing technology and mass spectrometry, which are used for test sample preparation. In-vitro diagnostic medical devices include reagents, reagent products, control materials, calibration materials, kits, instruments, apparatus, systems, equipment, pregnancy tests, urine test strips, blood sugar monitoring systems for diabetics and receptacles for medical specimens.
The top five companies covered are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Danaher (Beckman Coulter Inc), Abbott Laboratories Inc. and Thermo Fisher Scientific, Inc. Siemens Healthineers was the largest company in the in-vitro diagnostics market in 2017.
The countries covered are USA, China, Germany, Brazil, Japan, UK, Spain, Russia, France, Australia, Italy, India and rest of the world.
The global in-vitro diagnostics market was valued at around $56 billion in 2017. Asia Pacific was the largest region in the in-vitro diagnostics market in 2017, accounting for above 32% market share. The USA was the largest country in the market in 2017, accounting for under 21% market share.
Companies in this market are very active with multiple strategic collaborations and agreements. Top companies in the in-vitro diagnostic market are strategically partnering and collaborating with other companies to broaden their products, technologies and services.